LB
34
8
RRC
63
3
IFF
53
2
HRB
51
2
V
60
-6
INTU
51
2
TRV
53
-3
CSX
51
-2
M
20
-4
AXP
66
2
EQIX
60
-2
JNPR
46
3
NAVI
41
-3
INTC
35
-2
LLY
39
9
VRSN
53
3
XEL
67
2
AIV
68
-4
BEN
45
3
AES
39
-4
LB
34
8
RRC
63
3
IFF
53
2
HRB
51
2
V
60
-6
INTU
51
2
TRV
53
-3
CSX
51
-2
M
20
-4
AXP
66
2
EQIX
60
-2
JNPR
46
3
NAVI
41
-3
INTC
35
-2
LLY
39
9
VRSN
53
3
XEL
67
2
AIV
68
-4
BEN
45
3
AES
39
-4
Financhill
Back

Halozyme Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.25/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
44

HALO
Halozyme Therapeutics

Last Price:
45.73
Seasonality Move:
17.34%

7 Day Trial

ALL ACCESS PASS

$ 7

Access The Stock Grader Trading Tool From "The King Of Quants"

More details here...

Halozyme Therapeutics Price Quote

$45.73
-0.03 (-0.07%)
(Updated: November 21, 2024 at 5:55 PM ET)

Halozyme Therapeutics Key Stats

Sell
44
Halozyme Therapeutics (HALO) is a Sell
Day range:
$44.10 - $46.20
52-week range:
$33.15 - $65.53
Dividend yield:
0%
P/E ratio:
20.27
P/S ratio:
5.83
P/B ratio:
11.96%
Volume:
1.8M
Avg. volume:
1.8M
1-year change:
14.37%
Market cap:
$5.4B
Revenue:
$829.3M
EPS:
$3.02

How Much Does Halozyme Therapeutics Make?

Is Halozyme Therapeutics Growing As A Company?

  • What Is Halozyme Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.34%
  • What Is Halozyme Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0.72%

Halozyme Therapeutics Stock Price Performance

What Is Halozyme Therapeutics 52-Week High & Low?

Halozyme Therapeutics Price To Free Cash Flow

Is It Risky To Buy Halozyme Therapeutics?

Is Halozyme Therapeutics Cash Flow Positive?

  • What Is HALO Cash Flow From Operations?
    Cash flow from operations (TTM) is $403M
  • What Is Halozyme Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$222.4M
  • What Is Halozyme Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$300.5M

Halozyme Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    HALO return on invested capital is 22.41%
  • What Is Halozyme Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 20.54%
  • What Is HALO Return On Equity?
    ROE is a measure of profitability and is 156.62%

Halozyme Therapeutics Earnings Date & Stock Price

Halozyme Therapeutics Competitors

Halozyme Therapeutics Dividend Yield

Halozyme Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 72.13% 27.05%
Revenue: 34.28% 15.04%

Analyst Recommendations

Buy Recommendations: 3
Hold Recommendations: 5
Sell Recommendations: 0
Price Target: 62.44
Upside from Last Price: 36.46%

Major Shareholders

  • How many HALO shares are owned by institutional investors?
    203.7M HALO shares are owned by institutional investors
  • How many HALO shares are owned by insiders?
    11.5M HALO shares are owned by insiders